CanSino Biologics (06185): Abnormal trading fluctuations in A-shares. The mRNA platform is one of the technological platforms the company has laid out.

Kangxin Nuo Biology (06185) announced that the closing price of its A-shares has deviated by more than 30% cumulatively over three consecutive trading days on August 19, August 20, and August 21, 2026, which falls under the category of abnormal stock trading volatility. After self-examination, the company confirms that its production and business activities are currently normal, and internal operations are orderly. There have been no significant adjustments to the market environment or industry policies in which the company operates. Through self-examination and verification with the companys controlling shareholder and actual controller, as of the date of this announcement, the companys controlling shareholder and actual controller confirm that, except for information already publicly disclosed in designated information dissemination media, there are no significant matters that should be disclosed but have not been disclosed, including but not limited to plans for mergers and acquisitions, share issuance, debt restructuring, business restructuring, asset divestiture, and asset injection. The company has noted recent market developments concerning mRNA technology. The mRNA platform is one of the technology platforms the company is focusing on. The company is engaged in the development of mRNA vaccines for prevention and therapeutic biological products, as well as the development of related delivery systems. In terms of therapeutic areas, the company is advancing research and development of mRNA vaccines for the treatment of glioblastoma, rhabdomyosarcoma, and cervical cancer, as well as the development of In Vivo CAR-related therapies, all of which are currently in the early stages. As of the date of this announcement, the company has not found any media reports or market rumors that could significantly impact the trading price of the companys stocks that require clarification or response from the company. Upon verification, the company has not identified any other significant events that could greatly affect the company's stock price. During the period of this abnormal stock trading volatility, the companys directors, senior management, controlling shareholders, and their concerted actions have not engaged in buying or selling the companys shares.